The Role of Epigenetic Regulation in Cancer

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Genetics".

Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 5746

Special Issue Editors

Qingdao Central Hospital, The Second Affiliated Hospital of Medical College of Qingdao University, Qingdao, China
Interests: cancer biomarker; genetics; diabetes; ophthalmology
1. Laboratory for Clinical Bioinformatics, Sechenov First Moscow Medical University, Trubetskaya 8, Moscow 119048, Russia
2. Group for Genomic Analysis of Cell Signaling Systems, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya 16/10, Moscow 117997, Russia
Interests: molecular diagnostics; targeted cancer therapy; immunotherapy; chemotherapy; immune checkpoints; bioinformatics; machine learning; genomics; transcriptomics; RNA sequencing; molecular pathways; interactomics; second opinion diagnostic systems
David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
Interests: genomics; mRNA/miRNA expression; DNA-protein interaction

Special Issue Information

Dear Colleagues,

Genes and environment jointly determine the phenotype of organisms, both in physiological and pathological conditions. In recent decades, the emerging research on the chemical modification of DNA, RNA, and protein provides new insights into the epigenetic roles in the occurrence and progress of inflammation and cancer.

This special issue of biomolecules will focus on the latest progress in the role of epigenetic regulation in inflammation and cancer. Taking the epigenetic studies of RNA as an example, the roles, functions, and biological processes of m6A, m5C, m1a, m7G, ac4C, 2'- O methylation, and other types of chemical modifications in inflammation (eg: Alzheimer's disease, heart disease, type 2 diabetes, rheumatoid arthritis, and ankylosing spondylitis) and cancer are all our research areas of concern. In particular, we welcome original studies that are sufficiently novel, such as the single cell cancer epigenetics, regulatory roles of lncRNA and small RNA in epigenetics, epigenomics and social epigenomics, the use of multi-omics or other novel technical means to explore epigenetic regulation in inflammation-related diseases and cancer. In depth reviews in this direction are also welcome.

Prof. Dr. Ye Wang
Dr. Anton Buzdin
Prof. Dr. Xinmin Li
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chemical modification
  • epigenetic roles
  • cancer

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 1380 KiB  
Review
High-Fat Diet Related Lung Fibrosis-Epigenetic Regulation Matters
by Juntang Yang, Chenxi Liang, Lulu Liu, Lan Wang and Guoying Yu
Biomolecules 2023, 13(3), 558; https://doi.org/10.3390/biom13030558 - 18 Mar 2023
Cited by 5 | Viewed by 2318
Abstract
Pulmonary fibrosis (PF) is an interstitial lung disease characterized by the destruction of the pulmonary parenchyma caused by excessive extracellular matrix deposition. Despite the well-known etiological factors such as senescence, aberrant epithelial cell and fibroblast activation, and chronic inflammation, PF has recently been [...] Read more.
Pulmonary fibrosis (PF) is an interstitial lung disease characterized by the destruction of the pulmonary parenchyma caused by excessive extracellular matrix deposition. Despite the well-known etiological factors such as senescence, aberrant epithelial cell and fibroblast activation, and chronic inflammation, PF has recently been recognized as a metabolic disease and abnormal lipid signature was observed both in serum and bronchoalveolar lavage fluid (BALF) of PF patients and mice PF model. Clinically, observational studies suggest a significant link between high-fat diet (HFD) and PF as manifested by high intake of saturated fatty acids (SFAs) and meat increases the risk of PF and mice lung fibrosis. However, the possible mechanisms between HFD and PF remain unclear. In the current review we emphasize the diversity effects of the epigenetic dysregulation induced by HFD on the fibrotic factors such as epithelial cell injury, abnormal fibroblast activation and chronic inflammation. Finally, we discuss the potential ways for patients to improve their conditions and emphasize the prospect of targeted therapy based on epigenetic regulation for scientific researchers or drug developers. Full article
(This article belongs to the Special Issue The Role of Epigenetic Regulation in Cancer)
Show Figures

Figure 1

25 pages, 1079 KiB  
Review
Targeted Epigenetic Interventions in Cancer with an Emphasis on Pediatric Malignancies
by Zsuzsanna Gaál
Biomolecules 2023, 13(1), 61; https://doi.org/10.3390/biom13010061 - 28 Dec 2022
Viewed by 2757
Abstract
Over the past two decades, novel hallmarks of cancer have been described, including the altered epigenetic landscape of malignant diseases. In addition to the methylation and hyd-roxymethylation of DNA, numerous novel forms of histone modifications and nucleosome remodeling have been discovered, giving rise [...] Read more.
Over the past two decades, novel hallmarks of cancer have been described, including the altered epigenetic landscape of malignant diseases. In addition to the methylation and hyd-roxymethylation of DNA, numerous novel forms of histone modifications and nucleosome remodeling have been discovered, giving rise to a wide variety of targeted therapeutic interventions. DNA hypomethylating drugs, histone deacetylase inhibitors and agents targeting histone methylation machinery are of distinguished clinical significance. The major focus of this review is placed on targeted epigenetic interventions in the most common pediatric malignancies, including acute leukemias, brain and kidney tumors, neuroblastoma and soft tissue sarcomas. Upcoming novel challenges include specificity and potential undesirable side effects. Different epigenetic patterns of pediatric and adult cancers should be noted. Biological significance of epigenetic alterations highly depends on the tissue microenvironment and widespread interactions. An individualized treatment approach requires detailed genetic, epigenetic and metabolomic evaluation of cancer. Advances in molecular technologies and clinical translation may contribute to the development of novel pediatric anticancer treatment strategies, aiming for improved survival and better patient quality of life. Full article
(This article belongs to the Special Issue The Role of Epigenetic Regulation in Cancer)
Show Figures

Figure 1

Back to TopTop